Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Prakhar Agrawal has reiterated an Overweight rating on Structure Therapeutics (NASDAQ:GPCR) and maintained a $65 price target.
August 15, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Prakhar Agrawal has reiterated an Overweight rating on Structure Therapeutics (NASDAQ:GPCR) and maintained a $65 price target.
The reiteration of an Overweight rating and the maintenance of a $65 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100